News & Updates
Filter by Specialty:
Booster dose effective in reducing COVID-19 across ages in adults
The risk of COVID-19 is substantially reduced in adults who receive a third “booster” dose of the BNT162b2 vaccine regardless of their age, according to a study from Israel.
Booster dose effective in reducing COVID-19 across ages in adults
23 Feb 2022
Post-MPI statin use prevents MACE in patients with elevated coronary artery calcium score
Use of moderate- to high-intensity statins (MHIS) after myocardial perfusion imaging (MPI) leads to significantly fewer major adverse cardiovascular events (MACE) and is an independent negative predictor for 24-months MACE among patients with normal MPI and coronary artery calcium (CAC) score >300, a Singapore study has shown.
Post-MPI statin use prevents MACE in patients with elevated coronary artery calcium score
23 Feb 2022
Are patients with psoriatic arthritis at higher risk of death?
Patients with psoriatic arthritis (PsA) do not appear to be at increased risk of mortality from all causes, reveals a study. Moreover, the specific proportionate mortality rate (PMR) in this cohort is similar to that of the general population.
Are patients with psoriatic arthritis at higher risk of death?
23 Feb 2022
Lenvatinib-TACE combo a new first-line treatment alternative for advanced liver cancer?
In individuals with advanced hepatocellular carcinoma (HCC), the combination of transarterial chemoembolization (TACE) and lenvatinib as first-line treatment led to improved survival outcomes as opposed to lenvatinib monotherapy, according to findings of the phase III LAUNCH* trial.
Lenvatinib-TACE combo a new first-line treatment alternative for advanced liver cancer?
23 Feb 2022
AI as good as experts at detecting melanomas
Convolutional neural networks (CNN) can outperform less-experienced pathologists at discriminating melanomas from nevi, reports a recent study. For experienced pathologists, CNNs may still be helpful as a form of triage.
AI as good as experts at detecting melanomas
23 Feb 2022
Self-reported adverse reactions less likely after inactivated CZ02 vs mRNA-based BNT162b2
A prospective cohort study by the University of Hong Kong comparing the reactogenicity of coronavirus disease 2019 (COVID-19) vaccines reports a lower risk of self-reported adverse reactions following vaccination with inactivated CZ02 compared with mRNA-based BNT162b2.